Percutaneous coronary interventions in patients with renal insufficiency: A high-risk, under-studied cohort

American Heart Journal

Volumn 146, Issue 2, 2003, Pages 213-214

  Steinhubl, Steven R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

CARDIOGENIC SHOCK; COHORT ANALYSIS; COMORBIDITY; CORONARY ARTERY DISEASE; EDITORIAL; HIGH RISK POPULATION; HUMAN; KIDNEY FAILURE; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVASCULARIZATION; THROMBOCYTE AGGREGATION INHIBITION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0042627980     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00232-1     Document Type: Editorial

References (17)

1. Szczech LA, Best PJ, Crowley E, et al. Outcomes of patients with chronic renal insufficiency in the Bypass Angioplasty Revascularization Investigation. Circulation 2002;105:2253-8.
2. Rubenstein MH, Harrell LC, Sheynberg BV, et al. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation 2000;102:2966-72.
3. Best PJM, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002;39:1113-9.
4. Dacey LJ, Liu JY, Braxton JH, et al. Long-term survival of dialysis patients after coronary bypass grafting. Ann Thorac Surg 2002;74:458-62.
5. Masoudi FA, Plomondon ME, Magid DJ, Sales AE, Rumsfeld JS. Renal dysfunction and mortality after acute coronary syndromes [abstract]. Circulation 2002;106(2 Suppl):ll-401.
6. Jones CA, McQuillan GM, Kusek JW, et al. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998;32:992-9.
7. Ting HH, Tahirkheli NK, Berger PB, et al. Evaluation of long-term survival after successful percutaneous coronary intervention among patients with chronic renal failure. Am J Cardiol 2001;87:630-3.
8. Anderson KM, Califf RM, Stone GW, et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2001;37:2059-65.
9. Bhatt DL, Marso SP, Lincoff AM, et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000;35:922-8.
10. Tamberella M, Bhatt D, Chew D, et al. Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD Study). Am J Cardiol 2002;89:1429-31.
11. Steinhubl S, Talley J, Braden G, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event following percutaneous coronary intervention. Results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001;103:1403-9.
12. Reddan DN, O'Shea JC, Sarembock IJ, et al. Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). Am J Cardiol 2003;91:17-21.
13. Noris M, Remuzzi G. Uremic bleeding: Closing the circle after 30 years of controversies? Blood 1999;94:2569-74.
14. Best PJM, Lennon R, Gersh BJ, et al. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary intervention. Am Heart J 2003;146:345-50.
15. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
16. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
17. Jeremias A, Bhatt DL, Chew DP, et al. Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. Am J Cardiol 2002;89:1209-11.